On March 21st, 2022, Dr. Valorie Masuda MD received authorization under the Special Access Program (SAP) to treat six patients experiencing end-of-life distress with psilocybin and psychotherapy. GMP synthetic psilocybin was donated by Psygen Labs Inc., and Apex Labs Ltd. provided access to its psilocybin investigators’ brochure, in support of the SAP application. This is the first known case of…


Previous articlePsychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)
Next articlePT307 – Kathryn L. Tucker, JD – The Right to Try Act and the Battle for Psilocybin Access